Regulated information 1 July 2011

Galapagos increases share capital through warrant exercises

Mechelen, Belgium; 1 July 2011 – Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises.

Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in June 2011, Galapagos issued 8,386 new ordinary shares on 30 June 2011 for a total capital increase (including issuance premium) of €72,203.46. No member of the Board or Executive Committee exercised warrants.

To date, Galapagos' total share capital amounts to €142,920,142.06; the total number of securities conferring voting rights is 26,419,866, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities which confer voting rights is 2,613,758, which is also the total number of voting rights that may result from the exercise of these warrants. This total may be increased by a maximum of 934,240 warrants, should all warrants offered under recently created warrant plans (and for which the acceptance period is still ongoing) be accepted. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six programs in development and over 50 discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to €2.5 billion in downstream milestones, plus royalties. The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: **www.glpg.com**

CONTACT

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com